WO2013104892A8 - Application de composés à fortes doses par inhalation - Google Patents

Application de composés à fortes doses par inhalation Download PDF

Info

Publication number
WO2013104892A8
WO2013104892A8 PCT/GB2013/000015 GB2013000015W WO2013104892A8 WO 2013104892 A8 WO2013104892 A8 WO 2013104892A8 GB 2013000015 W GB2013000015 W GB 2013000015W WO 2013104892 A8 WO2013104892 A8 WO 2013104892A8
Authority
WO
WIPO (PCT)
Prior art keywords
application
via inhalation
compounds via
high dose
dose compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2013/000015
Other languages
English (en)
Other versions
WO2013104892A1 (fr
Inventor
Pedro Mendes
Ana GONÇALVES
Isabel Sequeira Lopes
Jason SUGGETT
Phillip Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hovione Inter AG
Original Assignee
Hovione Inter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hovione Inter AG filed Critical Hovione Inter AG
Publication of WO2013104892A1 publication Critical patent/WO2013104892A1/fr
Publication of WO2013104892A8 publication Critical patent/WO2013104892A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne l'administration de fortes doses de principes pharmaceutiquement actifs par inhalation. Une formulation pharmaceutique sous la forme d'une poudre se prêtant à l'inhalation qui comprend un ou plusieurs principes pharmaceutiquement actifs et un agent mucolytique et/ou un tampon, ladite formulation étant dépourvue de véhicule, est décrite.
PCT/GB2013/000015 2012-01-13 2013-01-14 Application de composés à fortes doses par inhalation Ceased WO2013104892A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT106094A PT106094A (pt) 2012-01-13 2012-01-13 Administração por inalação de formulações com dose elevada
PT106094 2012-01-13

Publications (2)

Publication Number Publication Date
WO2013104892A1 WO2013104892A1 (fr) 2013-07-18
WO2013104892A8 true WO2013104892A8 (fr) 2013-09-19

Family

ID=47605587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2013/000015 Ceased WO2013104892A1 (fr) 2012-01-13 2013-01-14 Application de composés à fortes doses par inhalation

Country Status (2)

Country Link
PT (1) PT106094A (fr)
WO (1) WO2013104892A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2754691C (fr) 2009-03-26 2019-07-30 Pulmatrix, Inc. Formulations de poudre seche et methodes pour traiter des maladies pulmonaires
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
RU2017144619A (ru) 2010-09-29 2019-02-20 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
EP3470057B1 (fr) 2010-09-29 2021-11-03 Pulmatrix Operating Company, Inc. Poudres sèches cationiques contenants un sel de magnésium
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
JP6473738B2 (ja) 2013-04-01 2019-02-20 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
WO2016013986A1 (fr) 2014-07-25 2016-01-28 Agency For Science, Technology And Research Compositions antibiotiques pour traiter des infections bactériennes
CN109745301A (zh) * 2017-11-08 2019-05-14 北京盈科瑞创新药物研究有限公司 一种羧甲司坦雾化吸入用溶液制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
DK2377557T3 (en) * 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
US20070123449A1 (en) * 2005-11-01 2007-05-31 Advanced Inhalation Research, Inc. High load particles for inhalation having rapid release properties
WO2007061454A1 (fr) * 2005-11-22 2007-05-31 Medpointe Healthcare Inc. Compositions comprenant de l'azelastine et procedes d'utilisation de celles-ci
JP2010534563A (ja) * 2007-07-24 2010-11-11 ネクスバイオ，インク． マイクロ粒子の作製のための技術
CA2754684A1 (fr) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Formulations a base de citrate de calcium et de lactate de calcium destinees a modifier les proprietes biophysiques des muqueuses
PT105065B (pt) * 2010-04-26 2012-07-31 Hovione Farmaciencia S A Um inalador simples de cápsulas
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition

Also Published As

Publication number Publication date
WO2013104892A1 (fr) 2013-07-18
PT106094A (pt) 2013-07-15

Similar Documents

Publication Publication Date Title
WO2013104892A8 (fr) Application de composés à fortes doses par inhalation
CA2865972C (fr) Poudres seches pouvant etre inhalees
PH12014502778B1 (en) Antibody formulation
WO2015054124A3 (fr) Inhalateur de poudre sèche
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
HK1221653A1 (zh) 用於呼吸递送三种或更多种活性剂的组合物、方法和系统
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX360315B (es) Composiciones farmaceuticas que comprenden un inhibidor de aromatasa.
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
MX2015014513A (es) Composicion que comprende sulfato de salbutamol.
WO2014028796A3 (fr) Préparation de liposomes desséchés utilisable dans des systèmes d'administration compressibles
MX363699B (es) Producto de comicronizacion que comprende acetato de ulipristal.
WO2014007772A3 (fr) Compositions d'inhalation contenant du glucose anhydre
WO2014007770A3 (fr) Compositions d'inhalation comprenant un corticostéroïde et du sorbitol
PH12014502619A1 (en) Novel dosage and formulation
WO2014007781A3 (fr) Compositions d'inhalation
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
MX2015015150A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
LV15003A (lv) Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
PH12015501179A1 (en) Fixed dose pharmaceutical composition comprising mometasone and azelastine
WO2013127539A3 (fr) Formulations pharmaceutiques
PT2617451T (pt) Conjunto para administrar um medicamento e inalador de dose única para a administração de um medicamento em pó que tenha esse conjunto
IN2013MU03567A (fr)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13701499

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 13701499

Country of ref document: EP

Kind code of ref document: A1